MedPath

Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer.

Not Applicable
Conditions
Advanced non-small cell lung cancer harboring EGFR mutation.
Registration Number
JPRN-UMIN000041251
Lead Sponsor
Central Japan Lung Study Group (CJLSG)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
557
Inclusion Criteria

Not provided

Exclusion Criteria

1. Not recieved afatinib or osimertinib as a monotherapy. 2. Recieved chemotherapy or immunotherapy before monotherapy of afatinib/osimertinib as systemic treatment for advanced non-small cell lung cancer. 3. Cases identified as ineligible by investigator.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath